ConforMIS Inc. (NASDAQ:CFMS) insider Daniel Steines sold 10,000 shares of ConforMIS stock in a transaction on Wednesday, October 12th. The stock was sold at an average price of $9.66, for a total value of $96,600.00. Following the transaction, the insider now directly owns 215,213 shares of the company’s stock, valued at approximately $2,078,957.58. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Daniel Steines also recently made the following trade(s):

  • On Monday, October 3rd, Daniel Steines sold 10,000 shares of ConforMIS stock. The stock was sold at an average price of $10.03, for a total value of $100,300.00.
  • On Friday, September 16th, Daniel Steines sold 30,000 shares of ConforMIS stock. The stock was sold at an average price of $9.09, for a total value of $272,700.00.

Shares of ConforMIS Inc. (NASDAQ:CFMS) traded down 2.83% on Friday, reaching $8.58. 478,988 shares of the company traded hands. The company’s market capitalization is $361.45 million. ConforMIS Inc. has a 52-week low of $4.80 and a 52-week high of $23.62. The firm has a 50-day moving average of $9.07 and a 200-day moving average of $8.83.

ConforMIS (NASDAQ:CFMS) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. ConforMIS had a negative return on equity of 45.30% and a negative net margin of 84.33%. The company earned $19.30 million during the quarter, compared to analysts’ expectations of $18.02 million. During the same quarter in the prior year, the business posted ($2.51) earnings per share. The company’s revenue for the quarter was up .5% compared to the same quarter last year. On average, equities research analysts forecast that ConforMIS Inc. will post ($1.40) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for ConforMIS (NASDAQ:CFMS)

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CFMS. Franklin Resources Inc. boosted its position in ConforMIS by 28.7% in the first quarter. Franklin Resources Inc. now owns 726,700 shares of the company’s stock valued at $7,813,000 after buying an additional 162,100 shares during the last quarter. Royce & Associates LP boosted its position in ConforMIS by 148.8% in the first quarter. Royce & Associates LP now owns 180,600 shares of the company’s stock valued at $1,941,000 after buying an additional 108,000 shares during the last quarter. Geode Capital Management LLC boosted its position in ConforMIS by 15.1% in the first quarter. Geode Capital Management LLC now owns 77,877 shares of the company’s stock valued at $837,000 after buying an additional 10,235 shares during the last quarter. Wellington Management Group LLP boosted its position in ConforMIS by 58.1% in the first quarter. Wellington Management Group LLP now owns 5,187,018 shares of the company’s stock valued at $55,760,000 after buying an additional 1,905,943 shares during the last quarter. Finally, Nuveen Asset Management LLC boosted its position in ConforMIS by 29.1% in the first quarter. Nuveen Asset Management LLC now owns 196,562 shares of the company’s stock valued at $2,113,000 after buying an additional 44,296 shares during the last quarter. 41.13% of the stock is owned by institutional investors.

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. cut their price target on ConforMIS from $11.00 to $8.00 and set a “neutral” rating for the company in a research note on Tuesday, August 9th. Zacks Investment Research raised ConforMIS from a “sell” rating to a “hold” rating in a research note on Friday, July 1st. SunTrust Banks Inc. assumed coverage on ConforMIS in a research note on Monday, September 19th. They set a “buy” rating and a $14.00 price target for the company. B. Riley assumed coverage on ConforMIS in a research note on Wednesday, September 21st. They set a “buy” rating and a $13.00 price target for the company. Finally, Oppenheimer Holdings Inc. lifted their price target on ConforMIS from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 9th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. ConforMIS presently has a consensus rating of “Buy” and an average price target of $14.86.

About ConforMIS

ConforMIS, Inc is a medical technology company that uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants. The Company’s products include iTotal CR, which is the cruciate-retaining, customized total knee replacement system to restore the natural shape of a patient’s knee; iTotal PS, which is the posterior cruciate ligament substituting, or posterior-stabilized, customized total knee replacement product to restore the natural shape of a patient’s knee; iDuo, which is the customized bicompartmental knee replacement system, and iUni, which is the customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee.

5 Day Chart for NASDAQ:CFMS

Receive News & Stock Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related stocks with our FREE daily email newsletter.